Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effects of indapamide SR 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

NCT06111885

Kidney Stone

RECRUITING PHASE2

Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension

NCT02646397

Chronic Kidney Disease

UNKNOWN PHASE4

The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure

NCT04455178

Hypertension

UNKNOWN PHASE4

Double Blind Crossover Comparison of Diuretics in the Young

NCT00429897

Low-Renin Hypertension

UNKNOWN NA

Comparison of Single and Combination Diuretics in Low-Renin Hypertension

NCT02351973

Hypertension

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Renal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Indapamide

Indapamide SR 1.5mg qd

Group Type EXPERIMENTAL

Indapamide

Intervention Type DRUG

Indapamide SR 1.5mg qd

Hydrochlorothiazide

Hydrochlorothiazide 25mg qd

Group Type ACTIVE_COMPARATOR

Hydrochlorothiazide

Intervention Type DRUG

Hydrochlorothiazide 25mg qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Indapamide

Indapamide SR 1.5mg qd

Intervention Type DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25mg qd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Creatinine clearance 30 to 90 mL/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation.
* Diagnosed hypertension according to guidelines or having taken anti-hypertension drugs.
* Aged between 65 and 85 years.
* Willingness to provide written, informed consent.
* Ability to adhere to study protocol.

Exclusion Criteria

* Secondary hypertension.
* Diabetes mellitus.
* Atrial flutter/atrial fibrillation.
* Symptoms of congestive heart failure (NYHA III-IV) or there is evidence that left ventricular EF \< 40%.
* Recent (\< 6 months) myocardial infarction or cerebrovascular ischemic symptoms.
* Recent (\< 3 months) or planned coronary revascularization: PCI (percutaneous coronary intervention)/CABG (coronary artery by-pass graft).
* Severe valvular heart disease.
* History of hypersensitivity to indapamide, thiazides or to any of the components of the products.
* Any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs.
* Participation to another investigational study in the last 3 months.

Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No